The CRL requests a quality process change Coherus and Junshi believe is readily addressable BLA resubmission anticipated by mid-summer 2022 with expected six month FDA review timeline Onsite inspections in China, impeded to date by…Original Article
Coherus and Junshi Biosciences Receive Complete Response Letter from U.S. FDA for Toripalimab BLA
